Log In
BCIQ
Print this Print this
 

CL-108

  Manage Alerts
Collapse Summary General Information
Company Charleston Laboratories Inc.
DescriptionBilayered tablet containing 12.5 mg immediate-release promethazine, an anti-emetic, with 7.5 mg hydrocodone and 325 mg acetaminophen
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsTreat moderate to severe acute pain and prevent opioid-induced nausea and vomiting (OINV)
Regulatory Designation
PartnerDaiichi Sankyo Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$650.0M

$100.0M

$550.0M


 Deals Details
Get a free BioCentury trial today